Eagle Pharmaceuticals: Q1 Earnings Insights

Shares of Eagle Pharmaceuticals EGRX remained unaffected at $55.02 after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 16.83% year over year to $0.84, which beat the estimate of $0.57.

Revenue of $46,020,000 lower by 7.56% from the same period last year, which missed the estimate of $51,100,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Eagle Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: May 11, 2020

Time: 08:02 PM ET

Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2Fhome%2Fdefault.aspx&eventid=2323967&sessionid=1&key=EDEC468D718914C24824955A2CD88AB4&regTag=&sourcepage=register

Technicals

Company's 52-week high was at $64.94

Company's 52-week low was at $33.80

Price action over last quarter: Up 25.07%

Company Profile

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.